BACKGROUND: Colorectal cancer (CRC) is the 3rd most common cancer worldwide and the Czech Republic has the 6th highest incidence of CRC worldwide. Large intestinal microbiota play in its etiopathogenesis important role. Bacteriocins are proteins, produced by bacteria from the Enterobacteriaceae family. The aim of our prospective study was to assess the colonization of large intestinal mucosa by Escherichia coli strains and to investigate their bacteriocin production. METHODS: A total of 30 consecutive patients with colorectal adenoma, CRA (17 men, 13 women, aged 39-79, mean age 63 ± 9), 30 patients with CRC (23 men, 7 women, aged 38-86, mean age 67 ± 11) and 20 healthy controls (9 men, 11 women, age 23-84, mean age 55 ± 15) were enrolled into prospective study. Mucosal biopsies were taken in the caecum, transverse colon and rectum during pancolonoscopy. Microbiological culture, isolation and identification of bacteria followed. Bacteriocin production was assessed by growth inhibition of indicator strains E. coli K12-Row, E. coli C6 (phi), and Shigella sonnei 17. Identification of bacteriocin-encoding determinants and E. coli phylogroups was performed using PCR methods. RESULTS: A total of 622 strains were isolated and further investigated. A significantly higher frequency of simultaneous production of colicins and microcins was revealed in the group of patients with CRC, when compared to patients with CRA, p = 0.031. A significantly higher frequency of E. coli phylogroup D was found in patients with CRC, when compared to controls, p = 0.044. A significantly higher prevalence of bacteriocinogeny was confirmed in patients with advanced adenoma when compared to patients with non-advanced adenoma, p = 0.010. Increasing bacteriocinogeny was associated with an increasing stage of CRC (assessed according to TNM classification). Either E. coli phylogroup B2 or E. coli phylogroup D were isolated in biopsies of patients with right-sided CRC. A statistically higher incidence of E. coli phylogroup B2 was found in patients with right-sided CRC when compared to patients with left-sided CRC, p = 0.028. CONCLUSIONS: Large intestinal mucosa of patients with more advanced colorectal neoplasia is colonized with more virulent strains of E. coli and higher production of bacteriocins is observed in these patients when compared to those with less advanced colorectal neoplasia.

Zobrazit více v PubMed

World Cancer Research Fund international. [http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php]

Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. The gut microbiome modulates colon tumorigenesis. MBio. 2013;4:e00692–13. doi: 10.1128/mBio.00692-13. PubMed DOI PMC

Yang T, Owen JL, Lightfoot YL, Kladde MP, Mohamadzadeh M. Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med. 2013;19:714–725. doi: 10.1016/j.molmed.2013.08.005. PubMed DOI PMC

Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G, Berretta M. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs. 2013;24:1069–1078. doi: 10.1097/CAD.0000000000000002. PubMed DOI

Rahman AU, Salajegheh A, Smith RA, Lam AK: BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects. Curr Cancer Drug Targets, in press., PubMed

Brown CL, Smith K, McCaughey L, Walker D. Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. Biochem Soc Trans. 2012;40:1549–1552. doi: 10.1042/BST20120241. PubMed DOI

Chumchalová J, Smarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha) 2003;48:111–115. doi: 10.1007/BF02931286. PubMed DOI

Messaoudi S, Manai M, Kergourlay G, Prévost H, Connil N, Chobert JM, Dousset X. Lactobacillus salivarius: bacteriocin and probiotic activity. Food Microbiol. 2013;36:296–304. doi: 10.1016/j.fm.2013.05.010. PubMed DOI

Farkas-Himsley H, Yu H. Purified colicin as cytotoxic agent of neoplasia: comparative study with crude colicin. Cytobios. 1985;42:193–207. PubMed

Musclow E, Farkas-Himsley H. Bacteriocin and flow cytometry in laboratory diagnosis of leukemic peripheral blood lymphocytes and bone marrow cells. Eur J Cancer Clin Oncol. 1983;19:163–171. doi: 10.1016/0277-5379(83)90413-3. PubMed DOI

Cornut G, Fortin C, Soulières D. Antineoplastic properties of bacteriocins: revisiting potential active agents. Am J Clin Oncol. 2008;31:399–404. doi: 10.1097/COC.0b013e31815e456d. PubMed DOI

Bures J, Horák V, Fixa B, Komárková O, Zaydlar K, Lonský V, Masurka V. Colicinogeny in colorectal cancer. Neoplasma. 1986;33:233–237. PubMed

Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M, Slatin S, Cavard D. Colicin biology. Microbiol Mol Biol Rev. 2007;71:158–229. doi: 10.1128/MMBR.00036-06. PubMed DOI PMC

Bures J, Smajs D, Kvetina J, Forstl M, Smarda J, Kohoutova D, Kunes M, Cyrany J, Tacheci I, Rejchrt S, Lesna J, Vorisek V, Kopacova M. Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol. 2011;17:609–617. doi: 10.3748/wjg.v17.i5.609. PubMed DOI PMC

Smajs D, Micenkova L, Smarda J, Vrba M, Sevcíkova A, Valisova Z, Woznicova V. Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor. BMC Microbiol. 2010;10:288. doi: 10.1186/1471-2180-10-288. PubMed DOI PMC

Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis. 2000;181:1753–1754. doi: 10.1086/315418. PubMed DOI

Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20:859–867. doi: 10.1158/1078-0432.CCR-13-1343. PubMed DOI

Lee S, Yu JK, Park K, Oh EJ, Kim SY, Park YJ. Phylogenetic groups and virulence factors in pathogenic and commensal strains of Escherichia coli and their association with blaCTX-M. Ann Clin Lab Sci. 2010;40:361–367. PubMed

Sobieszczańska BA, Duda-Madej AB, Turniak MB, Franiczek R, Kasprzykowska U, Duda AK, Rzeszutko M, Iwańczak B. Invasive properties, adhesion patterns and phylogroup profiles among Escherichia coli strains isolated from children with inflammatory bowel disease. Adv Clin Exp Med. 2012;21:591–599. PubMed

Nowrouzian FL, Oswald E. Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog. 2012;53:180–182. doi: 10.1016/j.micpath.2012.05.011. PubMed DOI

Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010;107:11537–11542. doi: 10.1073/pnas.1001261107. PubMed DOI PMC

Secher T, Samba-Louaka A, Oswald E, Nougayrède JP. Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PLoS One. 2013;8:e77157. doi: 10.1371/journal.pone.0077157. PubMed DOI PMC

Cougnoux A, Gibold L, Robin F, Dubois D, Pradel N, Darfeuille-Michaud A, Dalmasso G, Delmas J, Bonnet R. Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP. J Mol Biol. 2012;424:203–214. doi: 10.1016/j.jmb.2012.09.017. PubMed DOI

Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One. 2013;8:e56964. doi: 10.1371/journal.pone.0056964. PubMed DOI PMC

Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012;59:A4444. PubMed

Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–123. doi: 10.1126/science.1224820. PubMed DOI PMC

Fuska J, Fusková A, Smarda J, Mach J. Effect of colicin E3 on leukemia cells P388 in vitro. Experientia. 1979;35:406–407. doi: 10.1007/BF01964380. PubMed DOI

Mittelman M, Farkas-Himsley H, Haran-Ghera N. Recognition of T-cell murine leukemia by bacteriocin (colicin); correlation with transplantation experiments. Leuk Res. 1987;11:215–222. doi: 10.1016/0145-2126(87)90045-2. PubMed DOI

Smarda J, Obdrzalek V. The lethal effect of colicin E3 on HeLa cells in tissue cultures. IRCS Med Sci. 1977;5:524.

Smarda J, Obdrzalek V, Taborsky I, Mach J. The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells. Folia Microbiol (Praha) 1978;23:272–277. doi: 10.1007/BF02876680. PubMed DOI

Farkas-Himsley H, Cheung R, Tompkins WAF. Selective antitumor agents: bacteriocins from gram-negative bacteria. IRCS Med Sci. 1975;3:149–151.

Smarda J, Obdrzalek V. Incidence of colicinogenic strains among human Escherichia coli. J Basic Microbiol. 2001;41:367–374. doi: 10.1002/1521-4028(200112)41:6<367::AID-JOBM367>3.0.CO;2-X. PubMed DOI

Escherichia coli from biopsies differ in virulence genes between patients with colorectal neoplasia and healthy controls

Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia

Mitotic and apoptotic activity in colorectal neoplasia

Characterization of four Escherichia albertii isolates collected from animals living in Antarctica and Patagonia

Human extraintestinal pathogenic Escherichia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants

Anti-Outer membrane protein C antibodies in colorectal neoplasia

Microcin determinants are associated with B2 phylogroup of human fecal Escherichia coli isolates